Ovarian Cancer
Articles tagged with Ovarian Cancer
A common cholesterol drug may weaken ovarian cancer’s hidden shield
A new study found that a fluid surrounding many ovarian tumors, known as ascites, helps cancer cells survive and spread. Researchers discovered that a decades-old cholesterol drug, bezafibrate, can disrupt this protection by altering fat storage and iron control, making cancer cells more vulnerable to existing treatments.
National study examines genetic testing to inform follow-up care for cancer survivors
Low-cost color sensor device enables rapid detection of ovarian cancer biomarkers
Caregivers of ovarian cancer patients face high stress and major gaps in support
A new review highlights the emotional, physical, and financial challenges faced by caregivers of women living with ovarian cancer. Caregivers experience anxiety, depression, grief, and burnout, alongside practical barriers such as financial hardship and limited communication with healthcare providers.
Melatonin application increases effectiveness of autologous ovarian tissue transplantation, study reveals
Researchers found that melatonin increased vascularization and reduced apoptosis in ovarian grafts, improving their viability. The study used an absorbable sponge to apply melatonin to autologous ovarian tissue transplants in rats, revealing its potential as a treatment option for fertility preservation in young cancer patients.
Bowel and ovarian cancer cases rising among younger adults in England
Cancer cases are on the rise among younger adults in England, with a significant increase in bowel and ovarian cancer rates. The study found that excess weight is a key contributor, but it's unlikely to fully explain this trend, as trends in risk factors such as smoking and diet have been stable or improving over the past decade.
Deceptive ovarian cancer case mimics pelvic abscess, delaying diagnosis in postmenopausal woman
A rare case of mucinous ovarian carcinoma was reported in a postmenopausal woman, initially misdiagnosed as a pelvic abscess due to nonspecific symptoms and radiologic features. The diagnosis was confirmed after advanced imaging and tumor marker assessment. Early recognition is crucial for timely diagnosis and effective treatment of th...
New KIR-CAR T cell therapy shows promise in multiple solid cancers
The KIR-CAR T cell therapy has shown promising results in a Phase I clinical trial, demonstrating safety and increasing efficacy with higher doses. The treatment targets mesothelin, widely expressed on several solid tumor cancers, and limits side effects through its natural 'on-off' mechanism.
New antibody-drug conjugate shows clinical benefit for advanced platinum-resistant ovarian cancer
A phase I clinical trial found that QLS5132 demonstrated an objective response rate of 50% and a disease control rate of 94.4% in patients with late-stage, platinum-resistant ovarian cancer. The study also showed a favorable safety profile for the treatment.
Targeting senescent ADSCs in adipose tissue: Tongji University team paves new way for ovarian cancer therapy
Ovarian cancer cells induce adipose tissue dysfunction and ADSC senescence, creating favorable conditions for tumor metastasis. Targeting senescent ADSCs with dasatinib plus quercetin or resveratrol achieves remarkable efficacy in delaying tumor progression and reducing metastases.
Newly funded projects to develop more effective drugs with fewer side effects for hard-to-treat cancers
Insilico Medicine nominates ISM6200, a potential best-in-class selective NR3C1 inhibitor for ovarian cancer, Cushing’s Syndrome, hypercortisolism-associated obesity and glaucoma
ISM6200 is a potent, potentially best-in-class preclinical candidate targeting NR3C1 for the treatment of ovarian cancer, Hypercortisolism (Cushing’s Syndrome), and other disorders related to excess cortisol. The molecule demonstrates low DDI risks and higher in vivo efficacy across multiple animal models.
A redesigned endoscope offers a new way to look for early signs of ovarian cancer
A redesigned endoscope, called CAFE, offers a new way to detect early signs of ovarian cancer by combining high-resolution imaging with gentle cell collection. The device successfully imaged fallopian tube tissue and collected large numbers of epithelial cells, suggesting its potential for earlier disease detection.
UNC researchers publish findings in JAMA Network Open about impact of diagnostic wait time on ovarian cancer survival
A study of over 2,300 North Carolina women with ovarian cancer found that both quick and delayed diagnoses had worse survival rates than those diagnosed in the middle. Considering patient severity may improve outcomes for some symptomatic patients.
Tumor-informed liquid biopsy suggests structural-variant ddPCR can monitor high-grade serous ovarian cancer
A novel method for monitoring on-treatment disease burden in high-grade serous ovarian cancer uses tumor-informed breakpoints-spanning ddPCR, detecting superior sensitivity and specificity compared to real-time PCR. The approach may enable sensitive and specific detection of minimal residual disease and early relapse detection.
Hidden drug reservoirs in cancer cells could explain treatment resistance
Researchers mapped PARP inhibitors' distribution using advanced imaging techniques and patient ovarian tumour samples, revealing that build-up of drugs in lysosomes can trap and release certain drugs over time. This mechanism increases exposure to cancer cells, leading to variable treatment responses.
Overcoming ovarian cancer’s resistance to immunotherapy
A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...
Research alert: Rewiring immune system offers new path to better ovarian cancer treatment
Researchers at UC San Diego discover a new way to re-educate the immune system to attack ovarian cancer tumors by blocking protein FAK. The study offers hope for developing better treatments by turning the tumor environment from immune-suppressing to immune-activating.
UCLA researchers engineer CAR-T cells to target hard-to-treat solid tumors
The novel approach outperforms standard CAR-T cell therapy in preclinical studies using mouse models of glioblastoma and ovarian cancer. Armored CAR-T cells eliminate tumors, reshape the tumor environment, and boost immune-cell activity.
AI-boosted electronic nose detects ovarian cancer
Researchers at Linköping University have developed an AI-boosted electronic nose that can detect ovarian cancer from blood plasma samples with high accuracy. The method uses machine learning to identify patterns specific to the disease, making it a promising tool for early detection and improved survival rates.
Landmark Phase II study in platinum-resistant ovarian cancer to be presented at ESGO 2026
A Phase II study presents significant overall survival benefits for women with platinum-resistant ovarian cancer treated with elenagen plus gemcitabine. Longer exposure to elenagen correlates with longer survival after treatment discontinuation, suggesting a fundamentally different therapeutic approach.
Scientists now know why ovarian cancer spreads so rapidly in the abdomen
Ovarian cancer cells recruit protective mesothelial cells in abdominal fluid to form hybrid cell clusters that resist chemotherapy. These clusters use spike-like structures called invadopodia to invade surrounding tissue. The discovery opens new treatment possibilities and could help doctors monitor disease progression.
Surgical innovation cuts ovarian cancer risk by nearly 80%
A new study confirms that opportunistic salpingectomy (OS), which involves removing fallopian tubes during hysterectomy or tubal ligation, reduces the risk of serous ovarian cancer by nearly 80%. The procedure leaves ovaries intact, preserving hormone production and minimizing side effects.
Opportunistic salpingectomy for prevention of tubo-ovarian carcinoma
A study published in JAMA found that salpingectomy significantly lowers the risk of developing tubo-ovarian carcinoma. The procedure, typically performed during unrelated pelvic or abdominal surgery, is now recommended as a preventive measure for eligible women.
New AI tool helps doctors treat cancer patients after heart attack
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Five researchers at Italian Institute of Technology win new ERC funding
Five IIT researchers receive Proof-of-Concept grants to develop innovative health technologies, including a smart microscope and edible pills. These projects aim to tackle cancer, dyslexia, and diagnostics with cutting-edge technologies like quantum computing and near-infrared photonic chips.
Victoria’s Secret grant backs cutting-edge ovarian cancer research
Melanie Rutkowski's pioneering research may lead to novel immunotherapy treatments for ovarian cancer by understanding how faulty cellular signaling interacts with the microbiome. The grant aims to enhance immune system's ability to kill cancer cells and improve patient outcomes.
When ovarian cancer alters the abdominal cavity
Researchers found that ovarian cancer transforms the omentum into an environment that favors tumor spread. The study analyzed tissue samples from 15 patients and created a cell atlas of the omentum in diseased and healthy states.
Research validates laboratory model for studying high-grade serous ovarian cancer
A new study validates OVCAR3 as a reliable model for high-grade serous ovarian carcinoma, providing insights into disease behavior and potential therapeutic targets. The research also explores the effects of repurposed drugs on ovarian cancer cells, revealing promising results for treatment responses.
UT Health San Antonio awarded $3 million in CPRIT grants to bolster cancer research and prevention efforts in South Texas
UT Health San Antonio received $3 million in CPRIT grants to expand access to preventive salpingectomy, test novel methods to prevent liver cancer, and advance treatment for therapy-resistant metastatic breast cancer. These projects aim to improve cancer prevention, diagnosis, and treatment in South Texas.
Time burden in patients with metastatic breast and ovarian cancer from clinic and home demands
Studies show that patients with advanced ovarian and metastatic breast cancer dedicate approximately 7 hours per week to cancer-related tasks. Most participants report performing these tasks daily, impacting their time burden. The use of a mobile app facilitated the collection of detailed time-use data.
Cannabis derivatives could provide new ovarian cancer treatments
Lab studies found that a combination of THC and CBD kills ovarian cancer cells without harming healthy cells. The compounds may prevent metastasis and have minimal toxic effects, making them a promising alternative to current treatments.
First patient enrolled in GOG-3133/ FRAmework-01 phase 3 study evaluating sofetabart mipitecan (LY4170156), a novel ADC targeting folate receptor alpha (FRα), in recurrent ovarian cancer
Sofetabart mipitecan, a novel ADC targeting folate receptor alpha, shows robust clinical activity in patients with platinum-resistant ovarian cancer. The GOG-3133/ FRAmework-01 phase 3 study aims to expand treatment options for recurrent ovarian cancer and address the need for more effective therapies.
From lab to clinic: CU Anschutz launches Phase 1 clinical trial of promising combination therapy for resistant ovarian cancer
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
UTEP researcher finds potential new treatment for aggressive ovarian cancer
A UTEP research team found that Claudin-4, a protein increasing in ovarian cancer, may help tumors survive and hide from the immune system. Targeting Claudin-4 with a peptide and PARP inhibitor slows tumor growth and enhances the immune system's ability to fight cancer.
Targeting the matrix for anti-tumor T cell revival
Researchers have identified a protein complex that drives T cell exhaustion in tumors and show that disrupting it can revive exhausted anti-tumor CTLs. The study's findings offer new hope for improving the efficacy of cancer immunotherapy.
Blood test offers hope for more effective ovarian cancer treatment
Australian scientists have developed a new blood test that can identify women with ovarian cancer more likely to benefit from PARP inhibitor therapy, offering hope for more effective treatment. The test measures immune biomarkers and predicts which patients will respond to treatment.
Researchers at MIT develop new nanoparticles that stimulate the immune system to attack ovarian tumors
MIT researchers have developed new nanoparticles that deliver the immune-stimulating molecule IL-12 directly to ovarian tumors, eliciting a strong response and clearing tumors in over 80% of mice. This treatment combines with checkpoint inhibitors to launch an attack on cancer cells without causing side effects.
Scientists uncover new driver of ovarian cancer spread
Scientists have identified a new biomarker, F2R, which could improve ovarian cancer diagnosis and treatment. Elevated F2R levels are associated with shorter life spans, making it a valuable prognostic indicator.
First truly global picture of wide inequalities in care for women’s cancers
A major study of breast, cervical, and ovarian cancers found significant inequalities in global care, with many low- and middle-income countries (LMICs) diagnosing cancer at a later stage. Surgery was offered consistently, but treatment consistency varied, with LMICs often choosing mastectomy over breast-conserving surgery.
Trial enrollment and survival disparities among patients with advanced epithelial ovarian carcinoma
Black and Asian patients were underrepresented in clinical trials, leading to worse survival outcomes compared to white counterparts, despite similar progression-free survival rates. Equitable enrollment is crucial for access to cutting-edge treatments and long-term equity in cancer care.
To study treatment resistance in high-grade serous ovarian cancer, MSK researchers develop new approach
MSK researchers have developed a new method to study treatment resistance in high-grade serous ovarian cancer. By analyzing blood samples from 18 patients, they identified subpopulations of cancer cells with distinctive genetic features that contribute to recurrence. This approach may help develop targeted treatments for specific vulne...
Next-generation CAR T cells could expand solid cancer treatment options
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
Loss of Trp53 gene promotes tumor growth and immune suppression in ovarian cancer
The loss of Trp53 leads to more aggressive tumor growth and weaker immune responses in ovarian cancer. Researchers developed a mouse model that mimics human HGSC, showing how the disease progresses and evades the immune system.
NBL1: A key driver of ovarian cancer metastasis
Researchers identified NBL1 as a key driver of ovarian cancer metastasis through its activation of the Jak/Stat3 pathway. NBL1 expression levels strongly correlated with advanced clinical stage and poor survival outcomes.
UC Riverside startup secures grant to advance cancer therapy
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
New personalized risk score could improve ovarian cancer detection
Researchers developed Ovatools, a tool combining blood test results and age to identify women at higher risk of ovarian cancer. The approach is accurate for women over 50 and represents good value for the NHS, detecting more cancers earlier while remaining within affordability thresholds.
GLP-1 receptor agonists and cancer risk in adults with obesity
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
Unusual case of rare ovarian tumor mimicking pregnancy with successful treatment outcome
A 36-year-old woman was diagnosed with non-gestational ovarian choriocarcinoma, a rare and aggressive tumor that shares symptoms with pregnancy. She received chemotherapy and showed complete response to treatment.
Gauging the magnitude of missed opportunity for ovarian cancer prevention
A significant proportion of patients with high-grade serous ovarian cancer missed genetic testing and surgical prevention opportunities due to limited effective screening options and treatment limitations. The study emphasizes the importance of addressing these gaps to eradicate this aggressive form of ovarian cancer.
Selective expansion of TCF7-expressing tumor-reactive T cells from ovarian cancer
Researchers identify three tumor-reactive T cell subpopulations that exhibit selective expansion in ovarian cancer patients. CD8+ TCF7-expressing Tpex cells demonstrate self-renewal capacity and generate stem-like progenies, which may enhance persistence and specificity in current TIL therapy.
MD Anderson Research Highlights for August 7, 2025
A new multi-institutional study confirmed that the NSD2 protein can be targeted with a new drug, blocking it effectively reprogrammed DNA structure, reversed and prevented cancer growth in preclinical models of KRAS-mutant lung and pancreatic cancers. Targeting the brain-liver pathway with electronic wearables could prevent cancer-asso...
Global research trends in ovarian cancer care: A 23-year bibliometric analysis reveals key hotspots and future directions
A 23-year bibliometric analysis reveals key hotspots in ovarian cancer care, including quality of life, surgery, and nursing health. The study emphasizes the need for future research on psychological well-being and integrated care models to improve outcomes for women with ovarian cancer.
Novel radioimmunotherapy eradicates cancer stem cells in ovarian cancer model
Researchers developed a novel radioimmunotherapy that successfully eliminated cancer stem cells (CSCs) in preclinical models of ovarian cancer. The therapy, targeting CSC-associated biomarkers L1CAM + /CD133 + , showed significantly increased cytotoxicity compared to existing treatments.
Ovarian tumor immune landscapes offer clues to better therapy
A study of ovarian tumor immune landscapes reveals four distinct immunologic subtypes, with those with T cells surviving longer and having better outcomes. The researchers also found that myeloid cells play a key role in reestablishing the immune landscape upon recurrence.
Salk Professor Diana Hargreaves earns V Foundation award for pancreatic cancer research
Diana Hargreaves will receive $1 million to advance her project on improving immunotherapy in patients with pancreatic cancer. Her previous work identified better drug targets for cancers with SWI/SNF mutations, leading to breakthroughs in treating difficult-to-treat cancers.
University of Houston engineer leads team advancing early detection of ovarian cancer
A team led by University of Houston engineer Tianfu Wu aims to find better biomarkers for ovarian cancer using autoantibodies and machine learning. By detecting ovarian cancer earlier, mortality rates could be reduced by 10-30%.
New insights into ovarian cancer: why whole-genome doubling may hold the key to future HGSOC treatment strategies
A new study found that over 65% of ovarian cancer tumors exhibit whole-genome doubling, making them more resistant to treatments. WGD-high tumors suppress the immune response by repressing key pathways.
MD Anderson Research Highlights for July 16, 2025
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.